BRIEF published on 11/26/2024 at 00:25, 1 year 9 months ago NexgenRx Reports Q3 Growth and Announces Dividend Financial Results Revenue Increase Dividend Declaration SaaS Solutions EBITDA Growth
BRIEF published on 11/26/2024 at 00:25, 1 year 9 months ago NexgenRx annonce une croissance au troisième trimestre et un dividende Résultats Financiers Solutions SaaS Augmentation Des Revenus Croissance De L'EBITDA Déclaration De Dividendes
PRESS RELEASE published on 11/26/2024 at 00:20, 1 year 9 months ago NexgenRx Announces Third Quarter Results and Declaration of Divdend NexgenRx announces Q3 2024 financial results, with quarterly revenue up to $4,158,667 and increased positive EBITDA of $446,448. A dividend of $0.005 per share declared for shareholders Financial Results Revenue Dividend Q3 2024 NexgenRx
BRIEF published on 10/07/2024 at 23:35, 1 year 11 months ago NexgenRx Re-Appoints Charles Burns to Board of Directors Technology Solutions Board Appointment Canada NexgenRx Charles Burns
BRIEF published on 10/07/2024 at 23:35, 1 year 11 months ago NexgenRx reconduit Charles Burns au sein de son conseil d'administration Canada Nomination Au Conseil D'administration Solutions Technologiques NexgenRx Charles Burns
PRESS RELEASE published on 10/07/2024 at 23:30, 1 year 11 months ago NexgenRx Announces Director Re-Appointment NexgenRx Inc. announces re-appointment of Charles Burns to its Board of Directors. Company provides full-service Third-Party Administrator & Technology Solutions in Canada Board Of Directors Technology Solutions Third-party Administrator NexgenRx Inc. Charles Burns
BRIEF published on 10/01/2024 at 14:05, 1 year 11 months ago NexgenRx Appoints Linda Brennan to Board of Directors Board Of Directors Corporate Governance Appointment NexgenRx Linda Brennan
BRIEF published on 10/01/2024 at 14:05, 1 year 11 months ago NexgenRx nomme Linda Brennan au conseil d'administration Conseil D'administration Gouvernance D'Entreprise Rendez-vous NexgenRx Linda Brennan
PRESS RELEASE published on 10/01/2024 at 14:00, 1 year 11 months ago NexgenRx Announces New Director NexgenRx announces the appointment of Linda Brennan as a new member to its Board of Directors. Linda brings expertise in finance and corporate governance to the company Board Of Directors Appointment Finance NexgenRx Linda Brennan
BRIEF published on 07/18/2024 at 20:05, 2 years 1 month ago NexgenRx Announces Share Issuances Under Consulting Agreement Consulting Agreement Share Issuance NexgenRx PBM Management Services SaaS Model
Published on 09/11/2026 at 17:00, 2 hours 51 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/11/2026 at 17:00, 2 hours 51 minutes ago Critical Elements sélectionné pour inclusion dans le prospectus du sommet Canadien de l'investissement, mettant le projet en valeur auprès d'investisseurs mondiaux de premier plan
Published on 09/11/2026 at 15:25, 4 hours 26 minutes ago Revolve Signs Agreement to Acquire 9.6 MW Operating Wind Project in the US and Secures Project-Level Debt Financing with EDC and Vancity
Published on 09/11/2026 at 15:00, 4 hours 51 minutes ago Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update
Published on 09/11/2026 at 14:30, 5 hours 21 minutes ago AIAI Holdings Enters into Extended Lock-up Agreements to Protect Long-Term Stockholder Value
Published on 09/11/2026 at 19:44, 7 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 1 hour 36 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 18:00, 1 hour 51 minutes ago ROCTOOL: INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 09/11/2026 at 07:00, 12 hours 51 minutes ago Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 12 hours 51 minutes ago Transparency notification by Baltisse Group
Published on 09/11/2026 at 07:00, 12 hours 51 minutes ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 12 hours 51 minutes ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
